Eosinophilic pneumonia in patients treated with daptomycin: Review of the literature and US FDA adverse event reporting system reports

Drug Safety

Volumn 35, Issue 6, 2012, Pages 447-457

  Kim, Peter W ^a   Sorbello, Alfred F ^a   Wassel, Ronald T ^a   Pham, Tracy M ^a   Tonning, Joseph M ^a   Nambiar, Sumathi ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse drug reactions; Bacteraemia; Daptomycin; Dyspnoea; Eosinophilia; Fever; Hypoxaemia; Interstitial lung diseases; Pulmonary eosinophilia

Indexed keywords

AMIODARONE; AZATHIOPRINE; AZITHROMYCIN; BALSALAZIDE; BECLOMETASONE; CAFFEINE; CEFPIROME; CLARITHROMYCIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DAPSONE; DAPTOMYCIN; DICLOFENAC; ETODOLAC; FLUTICASONE; MEROPENEM; MESALAZINE; MINOCYCLINE; MONTELUKAST; NABUMETONE; NITROFURANTOIN; OXYGEN; PARACETAMOL; PROMETHAZINE; PYRIMETHAMINE; SALAZOSULFAPYRIDINE; SULFADOXINE; ZAFIRLUKAST;

ADULT; AGED; ARTIFICIAL VENTILATION; BACTERIAL ARTHRITIS; CHRONIC OSTEOMYELITIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIABETIC FOOT; DISKITIS; DRUG EXPOSURE; DRUG LABELING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL; EPIDURAL ABSCESS; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HOSPITAL DISCHARGE; HUMAN; LITERATURE; LOEFFLER PNEUMONIA; LUNG LAVAGE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; INCIDENCE; PULMONARY EOSINOPHILIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84861406845     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11597460-000000000-00000     Document Type: Review

References (20)

1. Cubicin-(daptomycin) package insert [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/021572s011lbl.pdf [Accessed 2011 Mar 7]
2. Lal Y, Assimacopoulos AP. Two cases of daptomycininduced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010 Mar 1; 50 (5): 737-40
3. US Food and Drug Administration. FDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm220273. htm. [Accessed 2011 Mar 7]
4. Cubicin-(daptomycin) package insert [online]. Available from URL: http://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?id=33819&CFID= 34544153&CFTOKEN=4f551a4fa2 efe2ed-90AB5A7F-F192-598D- C4B9E24D7FDD2672&jses sionid=ca3058b14dc53f534545 [Accessed 2011 Mar 7]
5. Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010 Mar; 11 (4): 615-25
6. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008 Apr 15; 46 (8): 1142-51 (Pubitemid 351589895)
7. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005 Jun 15; 191 (12): 2149-52 (Pubitemid 40800587)
8. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization [online]. Available from URL: http://www.meddramsso.com/ [Accessed 2011 Mar 7]
9. Philit F, Etienne-Maströanni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002 Nov 1; 166 (9): 1235-9 (Pubitemid 35222601)
10. Allen JN. Drug-induced eosinophilic lung disease. Clin Chest Med 2004 Mar; 25 (1): 77-88 (Pubitemid 38296333)
11. Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005 Jul; 60 (7): 841-57 (Pubitemid 40813804)
12. Solomon J, Schwarz M. Drug, toxin, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med 2006 Apr; 27 (2): 192-7
13. Hayes Jr D, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect 2007 Apr; 54 (4): e211-3 (Pubitemid 46395031)
14. Kakish E, Wiesner AM, Winstead PS, et al. Acute respiratory failure due to daptomycin induced eosinophilic pneumonia. Respir Med CME 2008; 1: 235-7
15. King TE. Idiopathic acute eosinophilic pneumonia. Up-ToDate-. Topic last updated December 1, 2009 [online]. Available from URL: http://www.uptodate.com/ contents/idiopathic-acute-eosinophilic-pneumonia?source=search- result&search=%22Idiopathic+acute+eosinophilic+pneum onia%22& selectedTitle=1%7E150 [Accessed 2010 Mar 1]
16. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higherthan-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25 (6): 381-92 (Pubitemid 34729136)
17. Surveillance Data Inc. (SDI), Inpatient Healthcare Utilization System (IHCarUS). Years 2004-2010. Data extracted September 2011
18. Kalogeropoulos AS, Tsiodras S, Loverdos D, et al. Eosinophilic pneumonia associated with daptomycin: a case report and a review of the literature. J Med Case Reports 2011 Jan 17; 5 (1): 13 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033840/pdf/1752-1947-5-13.pdf [Accessed 2011 October 24]
19. Miller BA, Gray A, Leblanc TW, et al. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis 2010 Jun 1; 50 (11): e63-8
20. Shinde A, Seifi A, DelRe S, et al. Daptomycin-induced pulmonary infiltrates with eosinophilia. J Infect 2009 Feb; 58 (2): 173-4